Semaglutide — Liver Health (MASLD/MASH)
TL;DR
FDA-accelerated approved (August 2025) for MASH with F2–F3 fibrosis. Wegovy formulation 2.4mg/wk SC. 63% MASH resolution vs 34% placebo; fibrosis improvement 37% vs 22% placebo (ESSENCE Phase 3). NOT indicated for cirrhosis — dedicated trial failed. Oral semaglutide (Rybelsus) has no MASLD data. Weight-independent hepatic mechanism is not established — no GLP-1R in human liver; all benefits are indirect.
Key Facts
- FDA approval: Wegovy semaglutide 2.4mg/wk SC — accelerated approval Aug 2025 for MASH F2–F3
- ESSENCE Phase 3: MASH resolution 62.9% vs 34.3% placebo; fibrosis ≥1-stage improvement 36.8% vs 22.4% placebo
- Meta-analysis 22 RCTs: MASH resolution RR=1.98 (significant); fibrosis regression RR=1.18 (NOT significant)
- Mechanism: No GLP-1R in human liver — all hepatic effects are indirect (insulin sensitization, reduced lipogenesis, anti-inflammatory)
- Cirrhosis: Phase 2 trial FAILED primary endpoint — NOT indicated for decompensated cirrhosis
- Oral semaglutide: No MASLD trial data — unknown efficacy vs SC formulation
- Monitoring: FibroScan/VCTE (≥30% LSM reduction); ELF (≥0.5 reduction); ALT (≥20% or ≥17 U/L reduction)
Evidence Quality
| Claim | Grade | PMIDs |
|---|---|---|
| MASH resolution (F2-F3) | High | 39412509, 41286982 |
| Fibrosis improvement (F2-F3) | High | 39412509 |
| Fibrosis regression in aggregate | High | 41286982 (NOT significant) |
| No GLP-1R in liver — indirect only | High | 40538007 |
| Greatest benefit ≥2.0mg/wk + ≥12 months | High | 41286982 |
| Phase 2 cirrhosis — primary endpoint NOT met | Moderate | 36934740 |
| AASLD guidance: F2-F3 indicated | High | 41201884 |
| Oral semaglutide MASLD efficacy | Gap | No data |
| Weight-independent mechanism | Very Low | Unproven |
Coaching Guidance
Say this:
- ✅ “Semaglutide has FDA approval for MASH with moderate-to-advanced fibrosis. It reduces liver inflammation and can help resolve MASH.”
- ✅ “The liver benefit is strongest at 2.4mg/wk for at least 12 months.”
- ✅ “Patients with MASH and F2–F3 fibrosis have the strongest evidence.”
Don’t say this:
- ❌ “It works on your liver independent of weight loss” — not established
- ❌ “It reverses fibrosis reliably” — aggregate evidence does not support this
- ❌ “Oral semaglutide has the same liver benefits” — no data exists
Key PMIDs
- PMID 39412509 — ESSENCE Phase 3
- PMID 41286982 — Meta-analysis 22 RCTs
- PMID 40985232 — NIT response
- PMID 40538007 — Mechanism review
- PMID 41201884 — AASLD guidance
- PMID 36934740 — Phase 2 cirrhosis trial
Related Notes
- GLP-1 RA NAION Safety Signal — ophthalmologic safety signal
- GLP-1 Muscle Preservation — body composition concern
- Retatrutide — triple agonist with MASLD data